Janssen Releases it's 3rd Annual U.S. Transparency Report
Thursday, April 4, 2019
On March 28, 2019, Janssen released its 3rd annual U.S. Transparency Report. The report demonstrates their commitment to responsible business practices that put patients first, including how they invest their resources, price medicines, and help people who need Janssen medicines get access to them.
The report shows that the average net price of their medicines in the U.S. has decreased for two years in a row, and they have maintained their significant investment in discovering and developing transformational medicines for patients facing some of the world’s most challenging diseases, investing 86% more in R&D than we spend on sales and marketing.
They also share ideas and perspectives on policy proposals, with the goal of building on what is working in our healthcare system while fixing what is not. And detail their plan to include list price and typical patient out-of-pocket costs in our U.S. pharmaceutical advertising.
The summary and more information about the DTC announcement are available on the Janssen U.S. website at Janssen.com/ustransparencyreportJanssen.com/ustransparencyreport.